Limits...
Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver.

Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, Wang ZJ, Zhao LQ, Chang WC - Korean J Radiol (2015)

Bottom Line: Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images.However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion.In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Seoul 05505, Korea. ; Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.

ABSTRACT
Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images. However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion. In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field.

No MeSH data available.


Simulated contrast enhancement curve of abdominal aorta and liver.Small amount of administered volume and gadolinium content of gadoxetate disodium (red line) can potentially shorten enhancement duration of contrast bolus and decrease magnitude of peak enhancement of contrast bolus compared with favorable contrast bolus curve (green line). This shape of gadoxetate disodium curve (red line) can pose challenges in capturing optimal arterial phase imaging.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4644741&req=5

Figure 1: Simulated contrast enhancement curve of abdominal aorta and liver.Small amount of administered volume and gadolinium content of gadoxetate disodium (red line) can potentially shorten enhancement duration of contrast bolus and decrease magnitude of peak enhancement of contrast bolus compared with favorable contrast bolus curve (green line). This shape of gadoxetate disodium curve (red line) can pose challenges in capturing optimal arterial phase imaging.

Mentions: In spite of the higher T1 relaxivity of gadoxetate disodium measured in human blood compared with other conventional extracellular MR contrasts (1314), this smaller administered volume and gadolinium content causes difficulties in obtaining consistently optimal arterialphase images. The smaller contrast volume can potentially shorten the enhancement duration of the contrast bolus and decrease the magnitude of the peak enhancement of the contrast bolus (Fig. 1) (1516). The lower gadolinium content can also result in a lower magnitude of the peak enhancement of the contrast bolus (1516). The effects of the small administered volume and gadolinium content are reflected in the weak arterial enhancement on images (67) and can pose challenges to capturing optimal arterial-phase imaging (10). Recent studies revealed that weak arterial enhancement can possibly affect the lesion conspicuity of hypervascular tumors such as HCCs and focal nodular hyperplasias during the arterial phase of gadoxetate-enhanced liver MR imaging in comparison with gadobenate dimeglumine-enhanced MR imaging (1718).


Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver.

Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, Wang ZJ, Zhao LQ, Chang WC - Korean J Radiol (2015)

Simulated contrast enhancement curve of abdominal aorta and liver.Small amount of administered volume and gadolinium content of gadoxetate disodium (red line) can potentially shorten enhancement duration of contrast bolus and decrease magnitude of peak enhancement of contrast bolus compared with favorable contrast bolus curve (green line). This shape of gadoxetate disodium curve (red line) can pose challenges in capturing optimal arterial phase imaging.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4644741&req=5

Figure 1: Simulated contrast enhancement curve of abdominal aorta and liver.Small amount of administered volume and gadolinium content of gadoxetate disodium (red line) can potentially shorten enhancement duration of contrast bolus and decrease magnitude of peak enhancement of contrast bolus compared with favorable contrast bolus curve (green line). This shape of gadoxetate disodium curve (red line) can pose challenges in capturing optimal arterial phase imaging.
Mentions: In spite of the higher T1 relaxivity of gadoxetate disodium measured in human blood compared with other conventional extracellular MR contrasts (1314), this smaller administered volume and gadolinium content causes difficulties in obtaining consistently optimal arterialphase images. The smaller contrast volume can potentially shorten the enhancement duration of the contrast bolus and decrease the magnitude of the peak enhancement of the contrast bolus (Fig. 1) (1516). The lower gadolinium content can also result in a lower magnitude of the peak enhancement of the contrast bolus (1516). The effects of the small administered volume and gadolinium content are reflected in the weak arterial enhancement on images (67) and can pose challenges to capturing optimal arterial-phase imaging (10). Recent studies revealed that weak arterial enhancement can possibly affect the lesion conspicuity of hypervascular tumors such as HCCs and focal nodular hyperplasias during the arterial phase of gadoxetate-enhanced liver MR imaging in comparison with gadobenate dimeglumine-enhanced MR imaging (1718).

Bottom Line: Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images.However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion.In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Seoul 05505, Korea. ; Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.

ABSTRACT
Gadoxetate disodium is a widely used magnetic resonance (MR) contrast agent for liver MR imaging, and it provides both dynamic and hepatobiliary phase images. However, acquiring optimal arterial phase images at liver MR using gadoxetate disodium is more challenging than using conventional extracellular MR contrast agent because of the small volume administered, the gadolinium content of the agent, and the common occurrence of transient severe motion. In this article, we identify the challenges in obtaining high-quality arterial-phase images of gadoxetate disodium-enhanced liver MR imaging and present strategies for optimizing arterial-phase imaging based on the thorough review of recent research in this field.

No MeSH data available.